Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery

Human Gene Therapy

Volumn 17, Issue 7, 2006, Pages 705-716

  Plog, Malinda S ^a   Guyre, Cheryl A ^a   Roberts, Bruce L ^a   Goldberg, Mark ^a   St George, Judith A ^a   Perricone, Michael A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; GLYCOPROTEIN GP 100; MELAN A; TUMOR ANTIGEN; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; BONE MARROW; CANCER; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; INFLAMMATORY CELL; INJECTION SITE REACTION; LUNG; LYMPH NODE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SAFETY; SKIN; SPLEEN; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DNA, VIRAL; FEMALE; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRADERMAL; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION;

ADENOVIRIDAE; ANIMALIA;

EID: 33746268509     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.705     Document Type: Article

References (41)

1. ALEMANY, R., and CURIEL, D.T. (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8, 1347-1353.
2. ALEMANY, R., SUZUKI, K., and CURIEL, D.T. (2000). Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81, 2605-2609.
3. AWASTHI, V., MEINKEN, G., SPRINGER, K., SRIVASTAVA, S.C., and FREIMUTH, P. (2004). Biodistribution of radioiodinated adenovirus fiber protein knob domain after intravenous injection in mice. J. Virol. 78, 6431-6438.
4. BIGBY, M., VARGAS, R., and SY, M.S. (1989). Production of hapten-specific T cell hybridomas and their use to study the effect of ultraviolet B irradiation on the development of contact hypersensitivity. J. Immunol. 143, 3867-3872.
5. BUTTERFIELD, L.H., JILANI, S.M., CHAKRABORTY, N.G., BUI, L.A., RIBAS, A., DISSETTE, V.B., LAU, R., GAMRADT, S.C., GLASPY, J.A., McBRIDE, W.H., MUKHERJI, B., and ECONOMOU, J.S. (1998). Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J. Immunol. 161, 5607-5613.
6. CHEN, D., MURPHY, B., SUNG, R., and BROMBERG, J.S. (2003). Adaptive and innate immune responses to gene transfer vectors: Role of cytokines and chemokines in vector function. Gene Ther. 10, 991-998.
7. DIAO, J., SMYTHE, J.A., SMYTH, C., ROWE, P.B., and ALEXANDER, I.E. (1999). Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene Ther. 6, 845-853.
8. EVERTS, M., KIM-PARK, S.A., PREUSS, M.A., PASSINEAU, M.J., GLASGOW, J.N., PEREBOEV, A.V., MAHASRESHTI, P.J., GRIZZLE, W.E., REYNOLDS, P.N., and CURIEL, D.T. (2005). Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors. Gene Ther. 12, 1042-1048.
9. GONG, J., CHEN, L., CHEN, D., KASHIWABA, M., MANOME, Y., TANAKA, T., and KUFE, D. (1997). Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther. 4, 1023-1028.
10. GONIN, P., and GAILLARD, C. (2004). Gene transfer vector biodistribution: Pivotal safety studies in clinical gene therapy development. Gene Ther. 11(Suppl. 1), S98-S108.
11. HACKETT, N.R., EL SAWY, T., LEE, L.Y., SILVA, I., O'LEARY, J., ROSENGART, T.K., and CRYSTAL, R.G. (2000). Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Mol. Ther. 2, 649-656.
12. HEHIR, K.M., ARMENTANO, D., CARDOZA, L.M., CHOQUETTE, T.L., BERTHELETTE, P.B., WHITE, G.A., COUTURE, L.A., EVERTON, MB., KEEGAN, J., MARTIN, J.M., PRATT, D.A., SMITH, M.P., SMITH, A.E., and WADSWORTH, S.C. (1996). Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J. Virol. 70, 8459-8467.
13. HILTUNEN, M.O., TURUNEN, M.P., TURUNEN, A.M., RISSANEN, T.T., LAITINEN, M., KOSMA, V.M., and YLA-HERTTUALA, S. (2000). Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J. 14, 2230-2236.
14. IMBODEN, M., SHI, F., PUGH, T.D., FREUD, A.G., THOM, N.J., HANK, J.A., HAO, Z., STAELIN, S.T., SONDEL, P.M., and MAHVI, D.M. (2003). Safety of interleukin-12 gene therapy against cancer: A murine biodistribution and toxicity study. Hum. Gene Ther. 14, 1037-1048.
15. JOOSS, K., and CHIRMULE, N. (2003). Immunity to adenovirus and adeno-associated viral vectors: Implications for gene therapy. Gene Ther. 10, 955-963.
16. JOOSS, K., YANG, Y., and WILSON, J.M. (1996). Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum. Gene Ther. 7, 1555-1566.
17. JOOSS, K., TURKA, L. A., and WILSON, J.M. (1998). Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther. 5, 309-319.
18. JUILLARD, V., VILLEFROY, P., GODFRIN, D., PAVIRANI, A., VENET, A., and GUILLET, J.G. (1995). Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. J. Immunol. 25, 3467-3473.
19. KAPLAN, J.M., YU, Q., PIRAINO, S.T., PENNINGTON, S.E., SHANKARA, S., WOODWORTH, L.A., and ROBERTS, B.L. (1999). Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163, 699-707.
20. KIMBER, I., KINNAIRD, A., PETERS, S.W., and MITCHELL, J.A. (1990). Correlation between lymphocyte proliferative responses and dendritic cell migration in regional lymph nodes following skin painting with contact-sensitizing agents. Int. Arch. Allergy Appl. Immunol. 93, 47-53.
21. LOWENSTEIN, P.R. (2003). Virology and immunology of gene therapy, or virology and immunology of high MOI infection with defective viruses. Gene Ther. 10, 933-934.
22. MATSUNAGA, K., HARA, K., IMAMURA, T., FUJIOKA, T., TAKATA, J., and KARUBE, Y. (2005). Technetium labeling of dextran incorporating cysteamine as a ligand. Nucl. Med. Biol. 32, 279-285.
23. MORRISSEY, R.E., HORVATH, C., SNYDER, E.A., PATRICK, J., and MACDONALD, J.S. (2002). Rodent nonclinical safety evaluation studies of SCH 58500, an adenoviral vector for the p53 gene. Toxicol. Sci. 65, 266-275.
24. NI, S., BERNT, K., GAGGAR, A., LI, Z.Y., KIEM, H.P., and LIEBER, A. (2005). Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum. Gene Ther. 16, 664-677.
25. PAIELLI, D.L., WING, M.S., ROGULSKI, K.R., GILBERT, J.D., KOLOZSVARY, A., KIM, J.H., HUGHES, J., SCHNELL, M., THOMPSON, T., and FREYTAG, S.O. (2000). Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol. Ther. 1, 263-274.
26. PERRICONE, M.A., CLAUSSEN, K.A., SMITH, K.A., KAPLAN, J.M., PIRAINO, S., SHANKARA, S., and ROBERTS, B.L. (2000). Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol. Ther. 1, 275-284.
27. PERROTTE, P., WOOD, M., SLATON, J.W., WILSON, D.R., PAGLIARO, L., PRICE, R.E., and DINNEY, C.P. (2000). Biosafety of in vivo adenovirus-p53 intravesical administration in mice. Urology 56, 155-159.
28. PETERS, A.H., DRUMM, J., FERRELL, C, ROTH, D.A., ROTH, D.M., McCAMAN, M., NOVAK, P.L., FRIEDMAN, J., ENGLER, R., and BRAUN, R.E. (2001). Absence of germline infection in male mice following intraventricular injection of adenovirus. Mol. Ther. 4, 603-613.
29. PEYRE, M., FLECK, R., HOCKLEY, D., GANDER, B., and SESARDIC, D. (2004). In vivo uptake of an experimental microencapsulated diphtheria vaccine following sub-cutaneous immunisation. Vaccine 22, 2430-2437.
30. RABEN, D., BUCHSBAUM, D.J., KHAZAELI, M.B., ROSENFELD, M.E., GILLESPIE, G.Y., GRIZZLE, W.E., LIU, T., and CURIEL, D.T. (1996). Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Ther. 3, 567-580.
31. SUNG, M.W., CHEN, S.H., THUNG, S.N., ZHANG, D.Y., HUANG, T.G., MANDELI, J.P., and WOO, S.L. (2002). Intratumoral delivery of adenovirus-mediated interleukin-12 gene in mice with metastatic cancer in the liver. Hum. Gene Ther. 13, 731-743.
32. TUOMELA, M., MALM, M., WALLEN, M., STANESCU, I., KROHN, K., and PETERSON, P. (2005). Biodistribution and general safety of a naked DNA plasmid, GTU-MultiHIV, in a rat, using a quantitative PCR method. Vaccine 23, 890-896.
33. VAJANTO, I., RISSANEN, T.T., RUTANEN, J., HILTUNEN, M.O., TUOMISTO, T.T., ARVE, K., NARVANEN, O., MANNINEN, H., RASANEN, H., HIPPELAINEN, M., ALHAVA, E., and YLA-HERTTUALA, S. (2002). Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J. Gene Med. 4, 371-380.
34. WAN, Y., BRAMSON, J., CARTER, R., GRAHAM, F., and GAULDIE, J. (1997). Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther. 8, 1355-1363.
35. WANG, Y., YANG, Z., LIU, S., KON, T., KROL, A., LI, C.Y., and YUAN, F, (2005). Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery. Br. J. Cancer 92, 1414-1420.
36. WILDNER, O., and MORRIS, J.C. (2002). Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: Dissemination, persistence, shedding, and pathogenicity. Hum. Gene Ther. 13, 101-112.
37. WOOD, M., PERROTTE, P., ONISHI, E., HARPER, M.E., DINNEY, C., PAGLIARO, L., and WILSON, D.R. (1999). Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther. 6, 367-372.
38. WORGALL, S., WOLFF, G., FALCK-PEDERSEN, E., and CRYSTAL, R.G. (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8, 37-44.
39. YE, X., GAO, O.P., PABIN, C., RAPER, S.E., and WILSON, J.M. (1998). Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum. Gene Ther. 9, 2135-2142.
40. ZHAI, Y., YANG, J.C., SPIESS, P., NISHIMURA, M.I., OVERWIJK, W.W., ROBERTS, B., RESTIFO, N.P., and ROSENBERG, S.A. (1997). Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J. Immunother. 20, 15-25.
41. 99mTc-labeled adenovirus knob (serotype 5). Gene Ther. 5, 798-808.